GSK plc’s announcement of a planned US withdrawal of the multiple myeloma drug Blenrep (belantamab mafodotin-blmf) a mere 15 days after disclosing that the DREAMM-3 trial was unsuccessful appears to set a new standard for speed of voluntary removal following a confirmatory trial failure.
The company’s action seemingly also reflects the FDA Oncology Center of Excellence’s push to remove “dangling” accelerated approval drugs more quickly, especially when other therapeutic alternatives exist, rather than letting them linger on
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?